Table 2 Baseline characteristics, comorbidities and outcomes within the screened population comparing Quantiferon gold negative (tested negative) and Quantiferon Gold positive (tested positive) groups
From: Tuberculosis screening practices and outcomes in an australian dialysis unit
Tested negative | Tested positive | Significance | ||
|---|---|---|---|---|
Total | 219 | 186 | 33 | |
Gender | Male | 111 (59.7%) | 23 (69.7%) | 0.28 |
Female | 75 (40.3%) | 10 (30.3%) | ||
Smoker | Never | 88 (47.3%) | 13 (39.4%) | 0.08 |
Former | 61 (32.8%) | 17 (51.5%) | ||
Current | 37 (19.9%) | 3 (9.1%) | ||
Age | 51 ± 12.7 | 56 ± 10.9 | 0.03 | |
Risk in country of origin | Low < 10 per 100,000 population per year | 93 (50.0%) | 4 (12.0%) | < 0.001 |
Intermediate 10-100 per 100,000 population per year | 47 (25.3%) | 9 (27.3%) | ||
High > 100 per 100,000 population per year | 46 (24.7%) | 20 (60.6%) | ||
Lung disease | 17 (9.1%) | 0 (0.0%) | 0.07 | |
Coronary disease | 43 (23.1%) | 11 (33.3%) | 0.21 | |
PVD | 25 (13.4%) | 7 (21.2%) | 0.24 | |
CVD | 18 (9.7%) | 4 (12.1%) | 0.66 | |
Diabetes | 102 (54.8%) | 16 (48.5%) | 0.50 | |
IS | 18 (9.7%) | 1 (3.0%) | 0.21 | |
Cancer | 16 (8.6%) | 1 (3.0%) | 0.27 | |
Active TB | 2 (1.1%) | 0 (0.0%) | 0.73 | |
Died | 26 (13.9%) | 2 (6.1%) | 0.20 |